Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31259921 | 1.00 | NFE2L2 (0.38) | NFE2L2KAT6AAKR1B1KCNA5KMT2A | |
| SCHEMBL6677573 | 0.87 | GAA (0.36) | KMT2AALDH1A1 | |
| SCHEMBL10864480 | 0.83 | CXCL8 (0.39) | KAT6AKCNA5KMT2AALDH1A1 | |
| SCHEMBL8798713 | 0.79 | PKM (0.42) | — | |
| SCHEMBL9870991 | 0.79 | AKR1B1 (0.41) | AKR1B1ALDH1A1 | |
| SCHEMBL395353 | 0.78 | KMT2A (0.43) | NFE2L2KMT2AL3MBTL1ALDH1A1HSD11B1 | |
| SCHEMBL11107609 | 0.78 | GAA (0.54) | KMT2AL3MBTL1TDP1 | |
| SCHEMBL10747298 | 0.78 | LOX (0.36) | ALDH1A1HSD11B1 | |
| SCHEMBL1124590 | 0.78 | HSD11B1 (0.40) | NFE2L2AKR1B1L3MBTL1ALDH1A1HSD11B1 | |
| SCHEMBL11169574 | 0.78 | CA2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119029300-A | Electrolyte and preparation method and application thereof | 湖南法恩莱特新能源科技有限公司 | 2024-11-26 | — | — | CN | claimed |
| CN-119029300-A | Electrolyte and preparation method and application thereof | 湖南法恩莱特新能源科技有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-119029300-A | Electrolyte and preparation method and application thereof | 湖南法恩莱特新能源科技有限公司 | 2024-11-26 | — | — | CN | disclosed |
| US-9855230-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-01-02 | — | — | US | disclosed |
| US-20170304239-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-10-26 | — | — | US | disclosed |
| WO-2016040084-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-17 | — | — | WO | disclosed |
| US-20090226819-A1 | ELECTROLYTIC SOLUTION AND SECONDARY BATTERY | SONY CORPORATION (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090226819-A1 | ELECTROLYTIC SOLUTION AND SECONDARY BATTERY | SONY CORPORATION (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| EP-0341489-B1 | Sulfonyl amino carbonyl triazolinones | BAYER AG (DE) | 1995-08-23 | — | — | EP | disclosed |
| US-4996208-A | Pesticidal thiazolopyrimidine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1991-02-26 | — | — | US | disclosed |
| EP-0341489-A1 | Sulfonyl amino carbonyl triazolinones | BAYER AG (DE) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304239-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | NFE2L2 2946/4885KAT6A 1497/4885AKR1B1 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.